Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study.

Ibba L, Gargiulo L, Alfano A, Cascio Ingurgio R, Narcisi A, Costanzo A, Valenti M

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience.

Gargiulo L, Ibba L, Vignoli CA, Facheris P, Valenti M, Costanzo A, Narcisi A

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.

Orsini D, Gargiulo L, Ibba L, Cascio Ingurgio R, Valenti M, Perugini C, Pacifico A, Maramao FS, Frascione P, Costanzo A, Narcisi A

Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals.

Fiorillo G, Ibba L, Gargiulo L, Vignoli CA, Alfano A, Cortese A, Toso F, Orsini D, Iacovelli P, Frascione P, Narcisi A, Costanzo A, Valenti M

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study.

Ibba L, Gargiulo L, Vignoli CA, Fiorillo G, Valenti M, Costanzo A, Narcisi A

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients.

Piscazzi F, Gargiulo L, Ibba L, Valenti M, Facheris P, Costanzo A, Narcisi A

Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa.

Vignoli CA, Gargiulo L, Sanna F, Narcisi A, Costanzo A

Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience.

Gargiulo L, Ibba L, Vignoli CA, Ferrucci SM, Mercuri SR, Malagoli P, Marzano AV, Barbareschi M, Bianchi VG, Valenti M, Costanzo A, Narcisi A

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.

Merola JF, Chiou AS, During E, Costanzo A, Foley P, Alfalasi A, Gogate S, Pinter A, Dodiuk-Gad R, Simon D, Tauber M, Weller R, Pereyra-Rodriguez JJ, Ardeleanu M, Wu J, Ozturk ZE

ANGPTL3 Deficiency and Risk of Hepatic Steatosis.

D'Erasmo L, Di Martino M, Neufeld T, Fraum TJ, Kang CJ, Burks KH, Di Costanzo A, Minicocci I, Bini S, Maranghi M, Pigna G, Labbadia G, Zheng J, Fierro D, Montali A, Ceci F, Catalano C, Davidson NO, Lucisano G, Nicolucci A, Arca M, Stitziel NO